Kenvue Inc (NYSE:KVUE) reported second quarter sales below Wall Street expectations, while also downwardly revising its full-year profit forecast.
The Neutrogena, Aveeno, Tylenol and Band-Aid owner reported net sales were down 4%, driven by weaker allergy and sun season demand in North America and shipment timing changes in China.
Earnings per share (EPS) of $0.29 were down from $0.32 in the year-ago period, slightly above estimates of $0.28.
For 2025, Kenvue said it now expects EPS in the range of $1 to $1.05, below its earlier guidance of $1.14. It also now expects revenue to be down low single digits.
“We are adjusting our outlook for 2025 to reflect the year-to-date results, as well as our current expectations for the second half of the year, considering the dynamic external environment and underlying business fundamentals,” Kenvue chief financial officer Amit Banati said in a statement.
“While current results do not reflect the company’s full potential, I am confident that we are taking the appropriate actions to deliver sustainable value for our shareholders.”
Shares of Kenvue added 0.5% at about $22 late morning on Thursday.